Cell Biology
Volume 3, Issue 1, January 2015, Pages: 19-24

Protective effect of resveratrol co-administered with high fat diet on blood glucose homeostasis and thyroid function in rabbits

Jimoh A.1, *, Tanko Y.1, Ahmed A.2, Mohammed A.1, Ayo J. O.3

1Department of Human Physiology, Ahmadu Bello University, Zaria, Nigeria

2Department of Pharmacognosy, Ahmadu Bello University, Zaria, Nigeria

3Department of Veterinary Physiology and Pharmacology, Ahmadu Bello University, Zaria, Nigeria

Email address:

(Jimoh A.)

To cite this article:

Jimoh A., Tanko Y., Ahmed A., Mohammed A., Ayo J. O.. Protective Effect of Resveratrol Co-Administered with High Fat Diet on Blood Glucose Homeostasis and Thyroid Function in Rabbits. Cell Biology. Vol. 3, No. 1, 2015, pp. 19-24. doi: 10.11648/j.cb.20150301.13


Abstract: Consumption of high fat diet rich in calorie has been associated with an increased incidence of diabetes mellitus. Deep underlying relation between diabetes mellitus and thyroid dysfunction has already been established. The aim of these experiments was to investigate the protective effect of resveratrol co-administration with high fat diet on blood glucose level and serum triiodothyronine (T3) and thyroxine (T4) levels in rabbits. Thirty rabbits divided into six group of five animal (n = 5) each were used for the experiment: Group 1 = normal control (C), group 2 = high fat diet (HFD) only, group 3 = resveratrol 200 mg/kg (R200), group 4 = resveratrol 400 mg/kg (R400), group 5 = HFD + R200 and group 6 = HFD + R400. Our finding demonstrate significant (P < 0.05) decrease in blood glucose level in HFD group treated with resveratrol compared with HFD group only after 5 weeks of the experimental protocol. Significant (P < 0.05) decrease in T3 and T4 levels were also observed in HFD group compared to the control group. Slight increase in T3 level was observed in HFD group treated with resveratrol but not significant (P > 0.05) compared to HFD group only. T4 level in the HFD group showed significant (P < 0.05) decrease compared to HFD group treated with resveratrol. In conclusion, the result demonstrated that co-administration of resveratrol with HFD decrease blood glucose level and improved T3 and T4 level in HFD fed rabbits.

Keywords: High Fat Diet, Blood Glucose Level, Rabbit, Thyroid Hormone


1. Introduction

The role of hyperthyroidism in diabetes was investigated in 1927 by Coller and Huggins; proving the association of hyperthyroidism, and worsening of diabetes. It was shown that surgical removal of parts of thyroid gland had an ameliorative effect on the restoration of glucose tolerance in hyperthyroid patients, suffering from co-existing diabetes [1]. There is a deep underlying relation between diabetes mellitus and thyroid dysfunction [2]. Thyroid hormones directly control insulin secretion. Hypothyroidism, result into a reduction in glucose-induced insulin secretion by beta cells, and the response of beta cells to glucose or catecholamine is increased in hyperthyroidism due to increase beta cells mass. Moreover, insulin clearance is increased in thyrotoxicosis [3,4].Thyroid hormones are insulin antagonists, both insulin and thyroid hormones are involved in cellular metabolism. Excess or deficit of the hormones can result in functional derangement of the other [5]. In hypothyroidism, glucose-induced insulin secretion by the β-cell is reduced while in hyperthyroidism, β-cell response to glucose or catecholamine stimulation appears to be increased and is accompanied by an increased β-cell mass [3,4]. The rates of glucose oxidation and glycogen synthesis are decreased in hypothyroidism due to down-regulation of glucose transporter GLUT5 in humans and impaired GLUT4 transporter in animal model [6]. Hyperthyroidism is associated with increased GLUT2 expression, as compared to the hypothyroid state [3]. Alterations in lipid metabolism further link thyroid hormone to insulin resistance [4].Thyroid hormones-dependent fatty acid uptake is tissue specific and may be increased in both thyrotoxicosis and hypothyroidism [7]. Thyroid hormone stimulates catecholamine action, which in turn increase lipolysis in adipose tissue, hence increasing circulating FAs [3]. The excessive consumption of high fat diet has been associated with an increased incidence of diabetes mellitus. They are enhanced by formation of oxidative stress form as a result of accumulation and adipose tissue expansion and consequently resulted into high levels of glucose which are potent inducers of cellular reactive oxygen species (ROS) [8,9,10]. Diabetes mellitus is considered as a common, growing, serious and costly, but potentially preventable public health problem [11]. Continuous consumption of calories-rich meals, junk food and sedentary lifestyle has culminated into an epidemic of diabetes worldwide. In general, High Fat Diet (HFD) is a nutritional condition that accounts for the largest incidence of metabolic syndrome in the world [12]. Defective insulin secretion leads to various metabolic aberrations in T2DM. The impairments include hyperglycaemia due to insulin-stimulated glucose uptake, up-regulated hepatic glucose production and dyslipidaemia [13]. Resveratrol (3, 5, 4’- trihydroxystilbene) is a polyphenol that occurs naturally in foods and drinks made from grapes and peanuts, and also in a number of herbal remedies, both alone and as part of plant extracts. Since then, studies have shown that resveratrol is a member of a class of compound called phytoalaxins, which plants use as a defense mechanism against pathogens, and it has also shown that it prevents or slows the progression of a wide variety of illnesses, including treatment of diabetes complications [14], cancer, cardiovascular disease [15], ischemic injuries and myocardial infarction [16.17]. Information on the protective effect of resveratrol on diabetes mellitus, and thyroid function in rabbits are scanty. The present study was undertaken to assess changes in blood glucose level, Triiodothyronine and thyroxine level in high fat diet fed rabbits.

2. Materials and Methods

2.1. Chemicals

All chemicals were obtained commercially and were of analytical grade: Cholesterol (Mumbai India, M. W 386.67, CAS No. 57-88-5, LoT No. 100413) and Mega resveratrol: 99 % pure trans-resveratrol Batch Number: MR 131120, Average particle size: 2.5μm Sigma USA).

2.2. Equipments

Kits for blood glucose level determination digital glucometer (Accu-check advantage meter Cat No. 870, 50 test strips/code chip Cat No./item No. 049272/4900, Roche Diagnostic USA,). Electronic eighing scale Model: EK 3052 balance, dissecting set, syringes and niddle (Sologuard Medical Device P.V.T Ltd., Chema-600 096, India, ML No. 750).

2.3. Experimental Animals

Seven weeks old male rabbits of different crossbreeds (New Zealand and local breed), weighing between 300 – 350 g raised in the Animal House, Department of Human Physiology Ahmadu Bello University Zaria, Nigeria were used for the study. The animals were kept in well-aerated laboratory cages in the Departmental Animal House, and were allowed to adjust to the laboratory conditions for a period of three weeks before the commencement of the experiment. They were fed with growers’ and starters’ mash (Vital Feeds Company Kaduna, Nigeria) and water were provided during the stabilizing period.

2.4. Induction of Diabetes Mellitus

The normal groups were fed with standard animal feeds only, while the high fat diet groups were fed with standard animal feeds + Cholesterol diet (10% Groundnut oil, 20% Groundnut mill and 2% cholesterol/kg/day) for the induction diabetes mellitus for the experimental period which lasted for eight weeks.

2.5. Resveratrol Preparation and Administration

Trans-resveratrol, due to its low solubility in water, was suspended in 10 g/L of carboxymethylcellulose (CMC), and administered orally according to the method of [18]

2.6. Ethical Approval

The rabbits were handled in accordance with the principles guiding the use and handling of experimental animals Ahmadu Bello University, Zaria, Nigeria.

2.7. Groupings

In the study, 30 rabbits weighing between 300 and 350 g were used, each group comprised five rabbits (n = 5). The experiment lasted for 8 weeks. The groupings were as follows:

Group 1: Received 10 g/L CMC each orally (C)

Group 2: Receive high fat diet as feed only (HFD)

Group 3: Received 200 mg/kg body weight of resveratrol orally (R200 mg/kg).

Group 4: Received 400 mg/kg body weight of resveratrol orally (R400 mg/kg).

Group 5: Received 200 mg/kg body weight of resveratrol and cholesterol diet (R200 mg/kg + HFD).

Group 6: Received 400 mg/kg body weight of resveratrol and cholesterol diet (R400 mg/kg + HFD) [19].

2.8. Blood Glucose Level Determination

Blood samples were collected from the marginal vein ear lobe of the rabbits at an interval of eight weeks on weekly bases. Determination of blood glucose level was done by the glucose-oxidase principle [20], using the digital glucometer (Accu-Check Advantage, Roche Diagnostic, Germany), and results were obtained as mg/dL [21].

2.9. Collection and Preparation of Serum Samples for Analysis

Eight weeks after the treatment period, all rabbits were subjected to light anaesthesia by exposing them to chloroform soaked in cotton wool placed in anaesthetic box covered with lid. Blood samples of about 3 ml were drawn from the heart of each sacrificed animal from all groups by cardiac puncture. The blood sample was put in EDTA bottle to prevent clotting, after with serum was extracted to determine the hormonal level of thyroid hormone.

2.10. Estimation of Serum T3 and T4 levels

Thyroid profile was estimated by using the enzyme-linked immunosorbent assay (ELISA) kits (T3 and T4) from sython Bioresearch, Inc, USA.thyroid hormone kit. T3 were estimated according to [22]. T4 were estimated according to [23]. The thyroid function was evaluated by determining the serum concentration of (T3 and T4) with a sensitivity of 20ng/L

2.11. Statistical Analysis

Blood glucose levels were expressed in mg/dL as mean ± SEM. The data were analyzed using ANOVA followed by Dunett’s post-hoc test to show multiple comparisons versus control group. Values of P < 0.05 were considered as significant [24].

3. Results

3.1. Blood Glucose Levels of Resveratrol Co-Administered with High Fat Diet Fed Rabbits

Table 1: shows the results of the effects resveratrol 200 mg/kg and 400 mg/kg of co-administered with high fat diet-fed rabbits, High fat diet-fed only, normal treated group and untreated group. The high fat diet fed rabbits showed significant (P < 0.05) increased in the blood glucose levels after 5 weeks of administration when compared to resveratrol treated group and normal control group. At 8 weeks of the experiment, HFD showed significant (P < 0.05) increase in blood glucose level with a value of 157.00 ± 14.47 mg/dL compared to HFD treated with resveratrol with decrease values of 119.00 ± 1.18 mg/dL for R200 + HFD and 110.20 ± 8.09 mg/dL for R400 + HFD respectively. The two doses of the resveratrol co-administered with high fat diet treated group significantly protect rise in blood glucose level when compared with the high fat diet only.

Table 1. Blood glucose levels of resveratrol co-administered with high fat diet fed rabbits for eight weeks of experimental period.

Group(n=5) (mg/dL) WK 0 WK 1 WK 2 WK 3 WK 4 WK 5 WK 6 WK 7 WK 8
Control 110.40±8.87 121.40±3.01 125.80±2.60 114.00±7.93 119.80±4.19 125.40±2.50 110.00±3.24 119.80±10.44a 120.00±7.07a
R200 112.00±5.01 116.60±4.38 117.00±4.67 115.00±4.11 112.00±5.24 112.00±3.56 113.80± 4.84 113.40 ± 7.01 119.20± .41
R400 108.00±2.43 117.80±2.04 116.40±1.97 105.00±2.41 117.80±3.38 114.60±3.30 117.00± 3.33 97.80 ± 2.33c 105.60±2.73
HFD 107.40±4.46 119.00±5.15 101.40±6.68 110.80±3.84 113.60±4.49 121.80±3.60b 135.60±3.71b 135.00±14.29b 157.00±14.47b
HFD+ R200 97.40 ± 4.65 112.80±3.65 106.60±5.81 108.40±6.17 110.60±2.91 101.40±5.03a 110.60±5.16a 122.80 ± 3.34a 119.00±1.18a
HFD+R400 96.80 ± 4.39 107.00±3.87 101.00±8.70 97.60±7.70 100.20±4.12 99.40 ± 4.14a 111.40±6.53a 116.20±11.55a 110.40 ± 8.09a

Values are expressed as mean ± SEM; n = 5 Value considered statistically when compared with HFD group: a = p < 0.05 significant wk = week of administration. Values with error bars having different superscripts letters are significant a,b,c, = p < 0.05 significant

Figure 1. Effect of co-administration of resveratrol and high-fat diet on serum T3 level in rabbits as compared with fed and unfed control group. Values are expressed as mean ± SEM; n = 5 Values with error bars having different superscripts letters are significant a,b,c, = p < 0.05 significant.

Figure 1 shows serum level of T3 in the group given resveratrol co-administered with HFD, resveratrol treated group alone and HFD group only. The result shows a significant (P < 0.05) decrease in T3 level in HFD group with a value of 0.78 ± 0.09 ng/ml when compared to control group with an increase value of 1.2 ± 0.09 ng/ml. The values recorded for resveratrol co-administered with high fat diet were 0.96 ± 0.05 ng/ml and 0.88 ± 0.09 ng/ml which also shows significant (P < 0.05) increase when compared with HFD group with a value of 0.78 ± 0.09 ng/ml.

Figure 2 shows serum level of T4 in the resveratrol co-administered with HFD groups, resveratrol treated groups alone and HFD group only. The values recorded for resveratrol co-administered with high fat diet R200 + HFD = 61.80 ± 2.52 ng/ml and R400 + HFD = 63.20 ± 1.28 ng/ml showed a significant (P < 0.05) increase, when compared to the decrease value observed in HFD group only with a value of 53.80 ± 1.88 ng/ml respectively. With respect to control group, the control group also shows significant (P < 0.05) increase in T4 level with a value of 67.60 ± 1.54 ng/ml when compared to the HFD only.

Figure 2. Effect of co-administration of resveratrol and high-fat diet on serum T4 level in rabbits as compared with fed and unfed control group Values are expressed as mean ± SEM; n = 5 Values with error bars having different superscripts letters are significant a,b,c = p < 0.05 significant.

4. Discussion

The highly predictive of new-onset T2DM is the presence of the metabolic syndrome (MetS) which increases the risk of T2DM [25,26]. T2DM is a complex disease caused by both environmental and genetic factors. It is marked by chronically elevated blood glucose concentrations, which result from defects in insulin production, insulin action, or a combination of both [27,28]. The aim of the present studies was to investigate the protective effect of resveratrol on blood glucose level and thyroid function of high fat diet- fed and unfed rabbits. In the present studies, the observed significant (P < 0.05) increase, in the blood glucose level in HFD group after 5 weeks of experimental protocol when compared to high fat diet groups treated with resveratrol indicates dysregulation in lipid metabolism. It is well known that a fat-enriched diet leads to the accumulation of adipose tissue and to the development of metabolic alterations associated with weight gain and diabetes mellitus [29]. Resveratrol has been show to improve insulin sensitivity and lowers body weight in rodent models of diet-induced obesity, which leads to the speculation about its potential as an anti-diabetic in humans [30]. The presence of polyphenol in resveratrol has been postulated to inhibit intestinal absorption of glucose and increase bioavailability of insulin, by stimulating secretion of insulin from β-cells are some of the way which it exert hypoglycaemic effect [31,32,33].

Stimulation of the activities of sirtuin 1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK) has demonstrated the anti-diabetic properties of resveratrol, and animals that lack AMPK fail to exhibit many of the normal responses to resveratrol [34,35]. The result of the present study is in agreement with the finding of [36], who demonstrate the hypoglycemic effect of resveratrol in enhancing insulin secretion in beta cells. The significant (P < 0.05) decrease observed in T3 and T4 level in HFD group compared to HFD + resveratrol indicate a state of hypothyroidism which impaired glucose oxidation and glycogen synthesis due to down-regulation of glucose transporter GLUT5 in humans and impaired GLUT4 transporter in animal model [7]. The result of the present study agreed with the finding of [7], who demonstrated the frequency of thyroid dysfunction among diabetes peoples. Thyroid hormones are insulin antagonists, both insulin and thyroid hormones are involved in cellular metabolism. Excess or deficit of any one can result in functional derangement of the other [7]. The observed decrease in T3 and T4 may be as a result of hyperglycemia observed in the HFD group only. Diabetes mellitus has been known to impair thyroid metabolism. At low insulin sensitivity, minor change in TSH levels is associated with marked changes in lipid risk factors and, thus, cardiovascular risk [37]. The observed decrease in blood glucose level and increase serum levels of T3 and T4 in HFD groups treated with resveratrol indicates protective effect of resveratrol against these disorders, since thyroid hormone have been known to stimulate thermogenesis, which is important in causing browning of white adipose tissue-a mechanism that burn, off excess fat in the body and improves glucose homeostasis [38,39].

5. Conclusion

High fat diet induced oxidative stress in rabbits, resulting in impairment of glucose metabolism and thyroid functions which was mitigated by resveratrol administration.

Acknowledgement

The authors wish to thank Mal Balla and ya’u technical staff of the Department of Human Physiology, Ahmadu Bello University Zaria, Nigeria. For their assistance throughout the period of this research work.


References

  1. Coller, F. A. and Huggins, C. B. (1927). Effect of hyperthyroidism upon diabetes mellitus: striking improvement in diabetes mellitus from thyroidectomy. Annals of Surgery, 86(6): 877-884.
  2. Brenta, G. Danzi, S. and Klein, I. (2010). Potential therapeutic applications of thyroid hormones analogs. Nature Clinical Practice of Endocrinology and Metabolism, 3(9): 632-640.
  3. Stanicka, S., Vondra, K., Pclikanova, T., Vlcck, P., Hill, M. and Zamrazil, V. (2005). Insulin sensitivity and counter-regulatory hormones in hyperthyroidism and during thyroid hormones replacement therapy. Clinical Chemistry and Laboratory Medicine, 43(7): 715-720.
  4. Mitrou, P., Raptis, S. A. and Dimitriadis, G. (2010). Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocrine Reviews, 31(5): 663-679.
  5. Singh, G., Gupta, V., Sharma, A. K. and Gupta, N. (2011). Frequently of thyroid dysfunction among diabetes in punjabi population. Advance in Bioresearch, 2: 3-9.
  6. Klieverik, L. P., Coomans, C. P. and Endert, E. (2009). Thyroid hormone effects on whole-body energy homeostasis and tissue specific fatty acid uptake in vivo. Endocrinology, 150: 56339-5648.
  7. Peppa, M., Varela, L. and Vazquez, M. J. (2010). Skeletal muscle insulin resistance in endocrine disease. Journal of Biomedicine and Biotechnology, 52(7): 8-15.
  8. Keaney, J. F., Larson, M. G. and Vasan, R. S. (2003). Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arteriosclerosis Thrombosis Vascular Biology, 23: 434-439.
  9. DeMarco, V. G., Johnson, M. S., Whaley-Connell, A. T. and Sowers, J. R. (2010). Cytokines abnormalities in the etiology of the cardiometabolic syndrome. Current Hypertens Rep, 12: 93-98.
  10. Otani, H. (2011). Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxidant Redox Signal, 15: 1911-1926.
  11. Adams, S. S., Imran, S., Wang, S. Mohammed, A. and Kok, S. (2011). The hypoglycemic effect of Pumpkins as Anti-Diabetic and functional medicines. Food research international, 44(4): 862-867.
  12. Buettner, R., Scholmerich, J. and Bollheimer, L. C. (2007). High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring), 15: 798-808.
  13. Baxter, J. D. and Webb, P. (2009). Thyroid hormones mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovery, 8(4): 308-320.
  14. Soufi, F. G., Mohammed-Nejad., D. and Ahmadieh, H. (2012). Resveratrol improves diabetic retinopathy possibly through stress-nuclear factor KB-apoptosis pathway. Pharmacological report, 64: 1504-1514.
  15. Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E.M., Labo, J., Ferruzzi, M. G., Daries, P. and Marambaud, P. (2010). Amp-activated protein kinase signaling activity by resviratrol modulates amyloid-beta peptide metabolism. Journal of Biological Chemistry, 285(12): 9100-9101.
  16. Sinha, K., Chaudhary, G. and Gupta, Y. K. (2002). Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Science, 71: 655-665.
  17. Lamuela-Raventos, R. M., Romero-Perez, A. I.,Waterhouse, A. L. Torre-Boronat, M. C. (1995). Direct HPCC Analysis of Cis and trans-Resveratrol andpiceid isomers in spanish red vitis viniferawines. Journal of Agricultural and food chemistry, 43(2): 281-283.
  18. Juan, M. E., Gonzalez-pons, E., Munuera, T., Ballester, J., Ridnguez-Gil, J. E and Planas, J. M. (2005). Trans- resveratrol, a natural antioxidant from grapes, increases sperm output in healthy rats. Journal of Nutrition, 135: 757-760.
  19. Joanne, M. A., Xiaomei, L., Christopher, Q. R., Brandi, P. and Min, Y. (2008). Resveratrol alleviates alcohol fatty liver in mice. American Journal of Physiology, 295(4): 833-842.
  20. Beach, E. F. and Turner, J. J. (1958). An enzymatic method for glucose determination in the body fluids. Clinical Chemistry, 4: 468.
  21. Rheney, C. C. and Kurk, K. K. (2000). Performance of three blood glucose meters. Annal of Pharmacotherapy, 34(3): 317-321.
  22. Schuurs, A. H. W. M. and Van-Weemen, B. K.. (1977). Review,E nzyme-Immunoassay. Clinical. Chemistry Acta, 8 (5): 1.
  23. Synder, P. J. and Utiger, R. D. (1972). Response to thyrotropin releasing hormones (TRH) in normal man. The Journal of Clinical Endocrinology and Metabolism, DOI:/10/1210/ 34-2-380.
  24. Duncan, R. C., Knapp, R. G. and Miller, M. C. (1977). Test of hypothesis in population means. In: Introductory Biostatistics for the health sciences, John Wiley and Sons Inc. NY: 71-96.
  25. Laaksonen, D. E., Lakka, H. M., Niskanen, L. K., Kaplan, G. A., Salonen, J. T. and Lakka, T. A. (2002). Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndromes in a prospective cohort study. American Journal of Epidemiology, 156: 1070-1077.
  26. Grundy, S., Brewer, B., Cleeman, J., Smith, S. and Lenfant, C. (2004). Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institude/American Heart Association Conference on scientific issues related to definition. Circulation, 109: 433-438.
  27. Dagher, Z., Park, Y. S., Asnaghi, V., I-Ioehn, T., Gerhardinger, C. and Lorenzi, M. (2004). Studies of rat and human retinas predict a role for the polyol pathway in human diabetes retinopathy. Diabetes, 53: 2401-2411.
  28. Metzger, B. E., Gabbe, S. G., Persson, B., Buchanan, T. A. Catalano, P. A. and Damm, P. (2010). International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycaemia in pregnancy. Diabetes care, 33(3): 676-682.
  29. Dewulf, E. M., Cani, P. D., Neyrinck, A. M., Possemiers, S., Van Holle, A. Muccioli, G. G., Deldicque, L., Bindels, L. B., Pachikian, B. D., Sohet, F. M., Mignolet, E., Francaux, M., Larondelle, Y. and Delzenne, N. M. (2011). Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. Journal of Nutrition and Biochemistry, 22: 712-722.
  30. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P. And Auwerx, J. (2006). Resveratrol Improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1[alpha]. Cell, 127(6): 1109-1122.
  31. Arai, I., Amagaya, S., Komatsu, Y.,Okada, M., Hayashi, T., Kasai, M., Arisawa, M. and Momose, Y. (1999). Improving effects of the extracts from Eugenia uniflora on hyperglycaemia and hypertriglyceryldemia in mice. Journal of Ethnopharmacology, 68: 307-314.
  32. Eddouks, M., Jouad, H., Maghrani, M., Lemhadri, A. and Burcelin, R. (2003). Inhibition of endogenous glucose production accounts for hypoglycaemic effect of Spergularia purpurea in streptozotocine mice. Phytomedicine, 10: 594-599.
  33. Ojewole, J. A. O. (2003). Hypoglycaemic effect of Sclerocarya birrea {A. Rich. HochSt.} (Anacardiaceae) stembark aqueous extract in rats. Phytomedicine, 10: 675-681.
  34. Feige, J. N., Lagouge, M., Canto, C., Strehle, A., Houten, S., Milne, J. C., Lambert, P. D., Mataki, C., Elliott, P. J. and Auwerx, J. (2008). Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metabolism, 8: 347-358.
  35. Um, J. H., Park, S. J., Kang, H. and Yang, S. (2009). AMPK-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes, 59: 554-563.
  36. Chen, W. P., Chi, T. C., Chuang, L. M. and Su, M. J. (2007). Resveratrol enhances insulin secretion by blocking KATP and KV channels of beta cells. Europeans Journal Pharmacology, 568: 269-277.
  37. Chubb, S. A., Davis, W. A. and Davis, T. M. E. (2005). Interactions among thyroid function, insulin sensitivity, and serum lipid concentration: The Fremantle Diabetes study. The Journal of Endocrinology and Metabolism, 90(9): 5317-5320.
  38. Decherf, S., Seugnet, I., Kouidhi, S., Lopez-Juarez, A., Clerget-Froidevaux, M. S. and Demenneix, B. A. (2010). Thyroid hormone exerts negative feedback on hypothalamic type 4 melanocortin receptor expression. Proceedings of the National Academy of Sciences of the United State of America, 107(7): 4471-4476.
  39. Lopez, M., Varela, L. and Vazquez, M. J. (2010). Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nature Medicine, 16(9): 1001-1008.

Article Tools
  Abstract
  PDF(328K)
Follow on us
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931